Precision BioSciences stock falls despite recent biotech sector strength

Published on 09/03/2026 at 19:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Precision BioSciences stock has eased back from recent levels even as the broader biotechnology sector shows ongoing activity. Investors are watching the small-cap gene-editing player’s valuation and recent trading data closely.

Precision BioSciences stock (ISIN US74019P1084) is trading below recent levels, with market data as of September 2, 2026 indicating a share price of about 7.45 dollars and a market capitalization near 205.6 million dollars, according to a Nasdaq biotechnology overview.

Small-cap biotech under pressure

Precision BioSciences, a micro-cap biotechnology company focused on gene-editing technologies, has seen its stock move lower in recent sessions. Market data compiled in early September 2026 show the shares at around 7.45 dollars, giving the company a market capitalization of roughly 205.6 million dollars as of September 2, 2026.

Additional quote information from a US stock portal shows a last traded share price of 7.81 dollars, with a documented decline of 0.60 dollars or 7.19% in late August 2026, and a price level of 7.81 dollars highlighted again as of August 31, 2026. These figures underline that the stock has recently traded in a narrow band between about 7.45 and 7.81 dollars as of the turn of the month.

Recent trading ranges and valuation context

Based on the available market snapshot, Precision BioSciences’ share price around 7.45 dollars is modestly below the late August quote of 7.81 dollars, implying a decline of 0.36 dollars or about 4.6% over that short period. For investors, this move comes against a backdrop of continued activity in the broader biotechnology sector, where other names have reported strong year-to-date gains or price moves near their 52-week highs.

The company’s market capitalization of about 205.6 million dollars as of September 2, 2026 places Precision BioSciences firmly in the micro-cap bracket, which typically implies higher volatility and sensitivity to clinical and funding news compared with larger biotechnology peers. The recent 7.19% single-day drop reported in late August 2026 illustrates this volatility and shows how quickly sentiment can shift around early-stage biotech names.

Go deeper

More background on Precision BioSciences

Investors can find further details on Precision BioSciences stock, recent filings and company announcements via our dedicated topic page and the company’s investor relations site.

All news on this ISIN Investor Relations

Gene-editing platform as key asset

Precision BioSciences’ core business centers on developing gene-editing therapies using its proprietary platform, positioning the company within a competitive and research-intensive segment of the biotechnology industry. While the latest detailed quarterly figures are not visible in the current market-data snapshots, investors typically focus on cash runway, research and development expenses, and partnership income when assessing such companies.

Historically, small gene-editing firms have faced periods of tight funding conditions but also episodes of strong price appreciation when clinical milestones or new partnerships are announced. Precision BioSciences’ current valuation around 205.6 million dollars as of early September 2026 suggests that the market is pricing in both the risks and the potential upside of its therapeutic pipeline.

Stock level and investor perspective

With Precision BioSciences stock trading close to the 7.45 dollar level as of September 2, 2026, investors will be watching upcoming corporate and clinical developments to gauge whether the recent dip from 7.81 dollars can reverse. The roughly 4.6% short-term decline and the earlier 7.19% single-session drop in late August highlight the importance of news flow and sector sentiment for micro-cap biotech names like Precision BioSciences.